Summary:Patient interest clusters heavily around drug–drug interactions, food effects, and therapeutic alternatives. Statins (especially Lipitor), biologics like Cosentyx, and common […]
By the time your next drug launches, a chatbot will already have an opinion about it — and 40 million
Why Pharmaceutical Companies Must Monitor AI Mentions Right Now There is a new drug representative calling on your patients and
How pharmaceutical brands are losing control of their narrative to AI answer engines — and the monitoring infrastructure they need
The Question Every Pharma Brand Team Is Ignoring Somewhere right now, a 54-year-old with newly diagnosed Type 2 diabetes is
What pharma’s regulatory, medical affairs, and brand teams need to do right now There is a scenario playing out across
Pharmaceutical brands are losing control of their product narrative — not in the press, not at the pharmacy counter, but
The Problem No One Is Watching Closely Enough Somewhere between a patient typing symptoms into a chatbot and a physician
Patients are asking ChatGPT about your drug. Physicians are consulting Gemini before prescribing. Regulators are building their own AI review
The Invisible Conversation Shaping Your Drug’s Reputation Somewhere right now, a patient is asking an AI chatbot whether their statin